These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26773371)

  • 1. Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.
    Cresti N; Lee J; Rourke E; Televantou D; Jamieson D; Verrill M; Boddy AV
    Eur J Cancer; 2016 Mar; 55():27-37. PubMed ID: 26773371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors.
    Furrer D; Lemieux J; Côté MA; Provencher L; Laflamme C; Barabé F; Jacob S; Michaud A; Diorio C
    Breast; 2016 Dec; 30():191-196. PubMed ID: 27788409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.
    Watrowski R; Castillo-Tong DC; Wolf A; Schuster E; Fischer MB; Speiser P; Zeillinger R
    Anticancer Res; 2015 Nov; 35(11):5901-4. PubMed ID: 26504013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer.
    Maae E; Andersen RF; Steffensen KD; Jakobsen EH; Brandslund I; Sørensen FB; Jakobsen A
    Anticancer Res; 2012 Sep; 32(9):3619-27. PubMed ID: 22993299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.
    Stanton SE; Ward MM; Christos P; Sanford R; Lam C; Cobham MV; Donovan D; Scheff RJ; Cigler T; Moore A; Vahdat LT; Lane ME; Chuang E
    BMC Cancer; 2015 Apr; 15():267. PubMed ID: 25885598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated UK Recommendations for HER2 assessment in breast cancer.
    Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
    J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Divisional role of quantitative HER2 testing in breast cancer.
    Yamamoto-Ibusuki M; Yamamoto Y; Fu P; Yamamoto S; Fujiwara S; Honda Y; Iyama K; Iwase H
    Breast Cancer; 2015 Mar; 22(2):161-71. PubMed ID: 23604955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients.
    Kara N; Karakus N; Ulusoy AN; Ozaslan C; Gungor B; Bagci H
    DNA Cell Biol; 2010 Jul; 29(7):387-92. PubMed ID: 20380571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients.
    Muendlein A; Hubalek M; Geller-Rhomberg S; Gasser K; Winder T; Drexel H; Decker T; Mueller-Holzner E; Chamson M; Marth C; Lang AH
    Eur J Cancer; 2014 Aug; 50(12):2134-41. PubMed ID: 24910416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
    Naidu R; Yip CH; Taib NA
    Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors.
    Justenhoven C; Pierl CB; Haas S; Fischer HP; Hamann U; Baisch C; Harth V; Spickenheuer A; Rabstein S; Vollmert C; Illig T; Pesch B; Brüning T; Dippon J; Ko YD; Brauch H
    Int J Cancer; 2009 May; 124(9):2077-81. PubMed ID: 19142864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.
    Cuadros M; Cano C; López FJ; López-Castro R; Concha A
    Pathobiology; 2013; 80(1):32-40. PubMed ID: 22832278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between HER2 and IL-6 genes polymorphisms and clinicopathological characteristics of breast cancer: significant role of genetic variability in specific breast cancer subtype.
    Bouhniz OE; Zaied S; Naija L; Bettaieb I; Rahal K; Driss M; Kenani A
    Clin Exp Med; 2020 Aug; 20(3):427-436. PubMed ID: 32372374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
    Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
    Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A positive role for PEA3 in HER2-mediated breast tumour progression.
    Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Young LS
    Br J Cancer; 2006 Nov; 95(10):1404-9. PubMed ID: 17060941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
    Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
    Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer.
    Nelson SE; Gould MN; Hampton JM; Trentham-Dietz A
    Breast Cancer Res; 2005; 7(3):R357-64. PubMed ID: 15987431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis.
    Zhang N; Huo Q; Wang X; Chen X; Long L; Guan X; Jiang L; Ma T; Hu W; Yang Q
    Gene; 2014 Feb; 535(2):170-6. PubMed ID: 24316488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.